When it comes to health and wellness, safety is key, especially when it comes to supplements that individuals consume to enhance their well-being. EffePharm, an innovator in NAD+ boosting ingredients, recognizes the importance of rigorous scientific evaluation to ensure the safety and efficacy of its products. To this end, they have produced UthPeak™, a patent-pending crystalline NMNH that is going through the Phase 1 study, a clinical trial that has been designed to assess its effects on human health and establish its safety profile.
Taking Nutraceuticals and Dietary Supplements to Market
Despite not falling within the same strict regulatory framework as pharmaceuticals, nutraceuticals and dietary supplements are not excluded from needing to conduct clinical studies. The supplement industry, while enjoying a less stringent regulatory pathway compared to pharmaceuticals, still bears the responsibility of ensuring product safety and efficacy.
In many jurisdictions, nutraceuticals and dietary supplement manufacturers must demonstrate that their products are safe and free of contaminants before they can be offered to the general public. This often involves rigorous testing and adherence to quality control standards. Furthermore, manufacturers may choose to conduct clinical trials to substantiate their marketing claims with scientific evidence, providing consumers with greater confidence in the product's benefits. This proactive approach can also provide a competitive advantage, differentiating a company's products from those without such rigorous scientific backing. For example, obtaining self-affirmed Generally Recognized As Safe (GRAS) certification can further enhance a supplement’s credibility and market acceptance.
To help manufacturers meet these requirements, clinical trials are conducted to evaluate the safety, efficacy, and bioavailability of their products. This initial phase of testing involves rigorous analyses to identify any potential contaminants, assess purity levels, and evaluate the material's stability and potential for interactions with other substances. These quality control measures are crucial for ensuring that the final supplement product is safe for human consumption and meets the intended specifications. Once the raw materials pass these stringent tests, further research, including clinical trials, may be conducted to assess the supplement's effects on various health markers and its overall potential to support well-being.
Uthpeak’s Clinical Trial – Phase 1

To further evaluate the safety and efficacy of UthPeak™, we have started a series of clinical trials. The Phase I clinical trial primarily focuses on determining the safety and tolerability of the supplement in human subjects. This phase is essential for establishing safe dosage ranges and identifying any potential side effects of this NAD+ booster supplement.
The study involves a group of healthy volunteers who receive different doses of UthPeak™ under careful medical supervision. Throughout the study, researchers closely monitor participants for any adverse reactions, assess how the supplement is metabolized and excreted by the body, and gather preliminary data on its potential effects.
Uthpeak’s Clinical Trial – Phase 2
Having established a solid foundation of safety data in Phase I, the Phase II clinical trial will delve deeper into the potential benefits of UthPeak™. This phase will focus on evaluating the efficacy of the supplement in improving various health markers. Specifically, this NMNH clinical test will assess UthPeak's impact on factors related to cardioprotection, energy enhancement, and liver protection, providing valuable insights into its potential to support overall well-being.
Furthermore, the Phase II study may explore additional biomarkers related to longevity and healthy aging, such as telomere length, inflammation markers, and measures of oxidative stress. This broader assessment will contribute to a more comprehensive understanding of UthPeak's potential to support long-term health and vitality, further solidifying its position as a leading NAD+ boosting supplement.
Investing in Research: Upholding Safety and Efficacy
EffePharm’s commitment to clinical trials demonstrates a dedication to scientific rigor and consumer safety. This dedication is further exemplified by UthPeak™’s recent achievement of self-affirmed GRAS status, a significant milestone that underscores our commitment to providing safe NAD+ boosting supplements.
This commitment to quality and transparency not only builds trust but also contributes to the advancement of the supplement industry as a whole, paving the way for a future where individuals can confidently embrace the potential benefits of NAD+ enhancement.
Comments